Nachrichten zur Neurocrine Biosciences Inc. Aktie

Insiderhandel: Aufsichtsrat verkauft Aktien von Neurocrine Biosciences im Wert von 1.002.743$

Lyons, Gary A. - Aufsichtsrat - Tag der Transaktion: 2021-06-10...…

Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

SAN DIEGO, June 1, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42nd Annual…

Neurocrine Biosciences: Pandemic Pressures And Few Pipeline Catalysts Continue To Weigh On NBIX

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

NEUROCRINE BIOSCIENCES INC: 8-K Report

8-K...…

Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference

SAN DIEGO, May 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets…

Neurocrine upgraded at Barclays despite Q1 earnings miss

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Inc (NBIX) Q1 2021 Earnings Call Transcript

NBIX earnings call for the period ending March 31, 2021....…

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2021 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences, Inc. 2021 Q1 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Inc Q1 adjusted earnings Miss Estimates

WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc (NBIX) reported earnings for first quarter that dropped from the same period last year.The…

Neurocrine Biosciences Supports Mental Health Month and Tardive Dyskinesia Awareness Week

SAN DIEGO, May 3, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its support of Mental Health Month…

Neurocrine Biosciences and Sentia Medical ink research collaboration agreement

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors

SAN DIEGO, April 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Johanna Mercier to…

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results

SAN DIEGO, April 14, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report first quarter…

Strength Seen in Neurocrine (NBIX): Can Its 11.1% Jump Turn into More Strength?

Neurocrine (NBIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…

Why Neurocrine Biosciences Stock Jumped Today

The stock is being added to a mid-cap index....…

Neurocrine Biosciences, O-I Glass jump on S&P index moves

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Centene, Neurocrine, Sarepta: Will These Out Of Favor Healthcare Stocks Outperform?

Out Of Favor Health Care Stocks includes healthcare and pharma names that have done reasonably well financially in recent years,…

Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference

SAN DIEGO , March 9, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will…

Neurocrine shares fall after mid-stage schizophrenia study results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences: Luvadaxistat Fails To Meet Primary Endpoint In Phase II INTERACT Study

TOKYO (dpa-AFX) - Neurocrine Biosciences (NBIX) said the investigational drug luvadaxistat did not meet primary endpoint in the phase II…

Neurocrine Biosciences to Present at the Cowen 41st Annual Health Care Conference

SAN DIEGO , Feb. 23, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will…

Neurocrine Biosciences Upping Marketing Spend To Support Its Platform

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

NEUROCRINE BIOSCIENCES INC: 10-K Report

10-K...…

More info. on Neurocrine Biosciences Q4 earnings

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Inc (NBIX) Q4 2020 Earnings Call Transcript

NBIX earnings call for the period ending December 31, 2020....…

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences, Inc. 2020 Q4 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences (NBIX) Q4 Earnings Top Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of 506.78% and -4.81%, respectively, for the quarter ended December 2020. Do the…

Neurocrine Biosciences Inc Q4 adjusted earnings Beat Estimates

WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc (NBIX) reported a profit for its fourth quarter that increased from the same period…

NEUROCRINE BIOSCIENCES INC: 8-K Report

8-K...…

Neurocrine Biosciences EPS beats by $0.01, misses on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results

SAN DIEGO , Feb. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today…

Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program

CAMBRIDGE, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that Neurocrine Biosciences,…

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results

SAN DIEGO , Jan. 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced…

Neurocrine, Ionis, Vertex: Underperforming Healthcare Stocks Poised To Recover

Our theme of Out Of Favor Health Care Stocks includes health care stocks that have witnessed strong Revenue growth and…

Neurocrine Bio sees Ingrezza sales of $993M in FY20

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones

SAN DIEGO , Jan. 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided…